|
🐜
|
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.
19 auth.
A. Palumbo,
A. Chanan-Khan,
K. Weisel,
A. Nooka,
T. Masszi,
M. Beksaç,
I. Spicka,
V. Hungria,
M. Munder,
M. Mateos,
...
T. Mark,
M. Qi,
J. Schecter,
H. Amin,
X. Qin,
W. Deraedt,
T. Ahmadi,
A. Spencer,
P. Sonneveld
|
10 |
2016 |
10
🐜
|
|
🐜
|
Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation.
29 auth.
B. Durie,
R. Kyle,
A. Belch,
W. Bensinger,
J. Bladé,
M. Boccadoro,
J. Child,
R. Comenzo,
B. Djulbegovic,
D. Fantl,
G. Gahrton,
J. Harousseau,
V. Hungria,
D. Joshua,
H. Ludwig,
...
J. Mehta,
A. Morales,
G. Morgan,
A. Nouel,
M. Oken,
R. Powles,
D. Roodman,
J. San Miguel,
K. Shimizu,
S. Singhal,
B. Sirohi,
P. Sonneveld,
G. Tricot,
B. V. Van Ness
|
8 |
2003 |
8
🐜
|
|
🐜
|
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
50 auth.
E. Kastritis,
G. Palladini,
M. Minnema,
A. Wechalekar,
A. Jaccard,
Hans C. Lee,
V. Sanchorawala,
S. Gibbs,
P. Mollee,
C. Venner,
Jin-Hai Lu,
S. Schönland,
M. Gatt,
Kenshi Suzuki,
Kihyun Kim,
...
M. Cibeira,
M. Beksaç,
E. Libby,
J. Valent,
V. Hungria,
S. Wong,
M. Rosenzweig,
N. Bumma,
A. Huart,
M. Dimopoulos,
D. Bhutani,
A. Waxman,
S. Goodman,
J. Zonder,
Selay Lam,
K. Song,
T. Hansen,
S. Manier,
W. Roeloffzen,
K. Jamroziak,
F. Kwok,
C. Shimazaki,
Jin-Seok Kim,
E. Crusoé,
T. Ahmadi,
N. Tran,
X. Qin,
S. Vasey,
B. Tromp,
J. Schecter,
B. Weiss,
S. Zhuang,
J. Vermeulen,
G. Merlini,
R. Comenzo
|
8 |
2021 |
8
🐜
|
|
🐜
|
International Myeloma Working Group recommendations for global myeloma care
21 auth.
H. Ludwig,
J. Miguel,
M. Dimopoulos,
A. Palumbo,
R. G. Sanz,
R. Powles,
S. Lentzsch,
W. Chen,
J. Hou,
A. Jurczyszyn,
...
K. Romeril,
R. Hájek,
E. Terpos,
K. Shimizu,
D. Joshua,
V. Hungria,
A. Morales,
D. Ben-yehuda,
Pia Sondergeld,
E. Zamagni,
B. Durie
|
7 |
2014 |
7
🐜
|
|
🐜
|
Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.
31 auth.
M. Mateos,
H. Nahi,
W. Legiec,
S. Grosicki,
V. Vorobyev,
I. Spicka,
V. Hungria,
Sibirina Korenkova,
N. Bahlis,
Max Flogegård,
J. Bladé,
P. Moreau,
M. Kaiser,
S. Iida,
J. Laubach,
...
H. Magen,
M. Cavo,
C. Hulin,
D. White,
V. De Stefano,
P. Clemens,
T. Masterson,
K. Lantz,
L. O’Rourke,
C. Heuck,
X. Qin,
D. Parasrampuria,
Zhilong Yuan,
Steven X. Xu,
M. Qi,
S. Usmani
|
7 |
2020 |
7
🐜
|
|
🐜
|
International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation
38 auth.
A. Palumbo,
O. Sezer,
R. Kyle,
J. Miguel,
R. Orlowski,
P. Moreau,
R. Niesvizky,
G. Morgan,
R. Comenzo,
P. Sonneveld,
Shaji K. Kumar,
R. Hájek,
S. Giralt,
S. Bringhen,
K. Anderson,
...
K. Anderson,
P. Richardson,
M. Cavo,
F. Davies,
J. Bladé,
Hermann Einsele,
M. Dimopoulos,
A. Spencer,
A. Dispenzieri,
T. Reiman,
K. Shimizu,
Jae Hoon Lee,
M. Attal,
M. Boccadoro,
M. Mateos,
Wei Chen,
H. Ludwig,
D. Joshua,
J. Chim,
V. Hungria,
I. Turesson,
B. Durie,
S. Lonial
|
7 |
2009 |
7
🐜
|
|
🐜
|
Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment.
21 auth.
P. Richardson,
V. Hungria,
S. Yoon,
M. Beksaç,
M. Dimopoulos,
A. Elghandour,
W. Jędrzejczak,
A. Guenther,
T. N. Nakorn,
N. Siritanaratkul,
...
R. Schlossman,
J. Hou,
P. Moreau,
S. Lonial,
J. H. Lee,
H. Einsele,
M. Sopala,
B. Bengoudifa,
C. Corrado,
F. Binlich,
J. San-Miguel
|
6 |
2016 |
6
🐜
|
|
🐜
|
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR.
17 auth.
M. Mateos,
P. Sonneveld,
V. Hungria,
A. Nooka,
J. Estell,
W. Barreto,
P. Corradini,
C. Min,
E. Medvedova,
K. Weisel,
...
Christopher Chiu,
J. Schecter,
H. Amin,
X. Qin,
J. Ukropec,
R. Kobos,
A. Spencer
|
6 |
2019 |
6
🐜
|
|
🐜
|
Central nervous system involvement by multiple myeloma: A multi‐institutional retrospective study of 172 patients in daily clinical practice
51 auth.
A. Jurczyszyn,
N. Grząśko,
A. Gozzetti,
J. Czepiel,
A. Cerase,
V. Hungria,
E. Crusoé,
Ana Luiza Miranda Silva Dias,
R. Vij,
M. Fiala,
J. Caers,
Leo Rasche,
A. Nooka,
S. Lonial,
D. Vesole,
...
S. Philip,
S. Gangatharan,
A. Druzd-Sitek,
J. Walewski,
A. Corso,
F. Cocito,
M. Vekemans,
Erden Atilla,
M. Beksaç,
X. Leleu,
J. Dávila,
A. Badros,
Ekta Aneja,
N. Abildgaard,
E. Kastritis,
D. Fantl,
N. Schutz,
T. Pika,
Aleksandra Butrym,
Magdalena Olszewska-Szopa,
L. Usnarska-Zubkiewicz,
S. Usmani,
H. Nahi,
C. Chim,
C. Shustik,
K. Mądry,
S. Lentzsch,
A. Świderska,
G. Helbig,
R. Guzicka-Kazimierczak,
N. Lendvai,
A. Waage,
K. T. Andersen,
H. Murakami,
S. Zweegman,
J. Castillo
|
6 |
2016 |
6
🐜
|
|
🐜
|
Expert review on soft‐tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations
38 auth.
L. Rosiñol,
M. Beksaç,
E. Zamagni,
N. V. D. van de Donk,
K. Anderson,
A. Badros,
J. Caers,
M. Cavo,
M. Dimopoulos,
A. Dispenzieri,
H. Einsele,
M. Engelhardt,
C. Fernández de Larrea,
G. Gahrton,
F. Gay,
...
R. Hájek,
V. Hungria,
A. Jurczyszyn,
N. Kröger,
R. Kyle,
F. Leal da Costa,
X. Leleu,
S. Lentzsch,
M. Mateos,
G. Merlini,
M. Mohty,
P. Moreau,
L. Rasche,
D. Reece,
O. Sezer,
P. Sonneveld,
S. Usmani,
K. Vanderkerken,
D. Vesole,
A. Waage,
S. Zweegman,
P. Richardson,
J. Bladé
|
6 |
2021 |
6
🐜
|
|
🐜
|
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials
36 auth.
L. Costa,
B. Derman,
S. Bal,
S. Sidana,
S. Chhabra,
R. Silbermann,
J. Ye,
G. Cook,
R. Cornell,
S. Holstein,
Q. Shi,
J. Omel,
N. Callander,
W. Chng,
V. Hungria,
...
Â. Maiolino,
E. Stadtmauer,
S. Giralt,
M. Pasquini,
A. Jakubowiak,
G. Morgan,
A. Krishnan,
G. Jackson,
M. Mohty,
M. Mateos,
M. Dimopoulos,
T. Facon,
A. Spencer,
J. Miguel,
P. Hari,
S. Usmani,
S. Manier,
P. McCarthy,
Shaji K. Kumar,
F. Gay,
B. Paiva
|
6 |
2020 |
6
🐜
|
